Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010250 | 0.89 | MAP4K4 (0.38) | KEAP1NFE2L2EPHX1BCHE | |
| SCHEMBL18502529 | 0.84 | POLB (0.46) | SMN1; SMN2KEAP1NFE2L2GFEREPHX1 | |
| SCHEMBL20673395 | 0.84 | SMN1; SMN2 (0.40) | SMN1; SMN2KEAP1NFE2L2GFEREPHX1 | |
| SCHEMBL19000034 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2KEAP1NFE2L2GFEREPHX1 | |
| SCHEMBL19022011 | 0.83 | KEAP1 (0.42) | SMN1; SMN2KEAP1NFE2L2GFEREPHX1 | |
| SCHEMBL19009037 | 0.83 | ALDH1A1 (0.34) | KEAP1NFE2L2EPHX1HPGDKMT2A | |
| SCHEMBL15142807 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2GFERCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2607208 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2GFERCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL15142809 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2GFERCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL26343670 | 0.80 | KEAP1 (0.46) | SMN1; SMN2KEAP1NFE2L2EPHX1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-03-26 | — | — | US | disclosed |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-01-24 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885KEAP1 1823/4885NFE2L2 1626/4885 |
| US-20190023687-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 2610/4885KEAP1 1861/4885NFE2L2 1792/4885 |
| US-20200095222-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885KEAP1 1823/4885NFE2L2 1626/4885 |
| US-10793553-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SMN1; SMN2 2610/4885KEAP1 1861/4885NFE2L2 1792/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SMN1; SMN2 2610/4885KEAP1 1861/4885NFE2L2 1792/4885 |
| US-10696649-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | SMN1; SMN2 1984/4885KEAP1 1823/4885NFE2L2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.